SHAPE of Portal Hypertension in Children

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions
Hypertension, Portal
Interventions
DRUG

SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)

The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.

DRUG

SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)

The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.

Trial Locations (1)

19104

RECRUITING

The Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Thomas Jefferson University

OTHER